Systematic review / meta-analysis / 2019
Combining Astragalus-based Chinese medicines with chemotherapy was linked to improved tumor response rate and fewer adverse effects in colorectal cancer patients.
A meta-analysis of 22 studies involving 1,409 patients evaluated Astragalus-based Chinese medicines combined with chemotherapy versus chemotherapy alone for colorectal cancer. The combination was associated with an increased tumor response rate (RR: 1.52; 95% CI: 1.24-1.87; p < 0.0001) and improved quality of life on the KPS scale (RR: 2.51; 95% CI: 1.85-3.42; p < 0.00001). It also reduced adverse reactions such as neutropenia, anemia, thrombocytopenia, nausea/vomiting, diarrhea, and neurotoxicity, while hepatic and renal dysfunction did not differ significantly between groups.
- Study type
- Meta-analysis
- Who was studied
- 1,409 subjects with colorectal cancer across 22 studies
- What was measured
- Tumor response rate, quality of life (KPS), adverse reactions
THE PAPER
Meta-Analysis of Astragalus-Containing Traditional Chinese Medicine Combined With Chemotherapy for Colorectal Cancer: Efficacy and Safety to Tumor Response.
Lin S, An X, Guo Y, Gu J, Xie T, Wu Q, Sui X. Front Oncol, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.